New Phase 3 trial: AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
🇺🇸 ClinicalTrials.gov · Thu 12 Nov 2026
Novo Nordisk A/S. Condition: Type 2 Diabetes. Intervention: Zenagamtide, Semaglutide, Placebo. NCT07931573.
ClinicalTrials.gov record: ClinicalTrials.gov ↗
Brief written by VigiEye from the company's press release. Claims are the company's own. AI-assisted; check the source before acting.
More Clinical trials
All →
Clinical trialsCompany releaseCalidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
🇺🇸 Calidi Biotherapeutics, Inc. (CLDI) · Fri 13 Nov 2026
Clinical trialsCompany releaseIRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
🇺🇸 IRulya Therapeutics Inc. (IRLA) · Fri 13 Nov 2026
Clinical trialsCompany releaseMacroGenics reports $288M cash and 2028 runway, putting B7-H3 ADC MGC026 in head and neck cancer first
🇺🇸 Macrogenics Inc (MGNX) · Fri 13 Nov 2026
Clinical trialsCompany releaseCerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
🇺🇸 Cerenome, Inc. (CNSY) · Fri 13 Nov 2026
Clinical trialsCompany releaseCuris reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
🇺🇸 Curis Inc (CRIS) · Fri 13 Nov 2026
Clinical trialsCompany releaseBluejay completes SYMON-II enrolment for Symphony IL-6 sepsis test, eyes 510(k) filing in H1 2027
🇺🇸 Bluejay Diagnostics, Inc. (BJDX) · Fri 13 Nov 2026